FLT3 and acute myeloid leukemia: In the case of newly diagnosed patients with FLT3‐ITD, the administration of the FLT3 inhibitor midostaurin has been approved together with conventional induction therapy, as well as gilteritinib, which is a more potent and specific FLT3 inhibitor, as monotherapy for relapsed/refractory FLT3‐ITD positive AML.67